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Abstract
Hypertension is considered as a low-grade inflammatory disease, with adaptive immunity being an important mediator of
this pathology. TLR4 may have a role in the development of several cardiovascular diseases; however, little is known about
its participation in hypertension. We aimed to investigate whether TLR4 activation due to increased activity of the renin-
angiotensin system (RAS) contributes to hypertension and its associated endothelial dysfunction. For this, we used aortic
segments from Wistar rats treated with a non-specific IgG (1 mg/day) and SHRs treated with losartan (15 mg/kg?day), the
non-specific IgG or the neutralizing antibody anti-TLR4 (1 mg/day), as well as cultured vascular smooth muscle cells (VSMC)
from Wistar and SHRs. TLR4 mRNA levels were greater in the VSMC and aortas from SHRs compared with Wistar rats;
losartan treatment reduced those levels in the SHRs. Treatment of the SHRs with the anti-TLR4 antibody: 1) reduced the
increased blood pressure, heart rate and phenylephrine-induced contraction while it improved the impaired acetylcholine-
induced relaxation; 2) increased the potentiation of phenylephrine contraction after endothelium removal; and 3) abolished
the inhibitory effects of tiron, apocynin and catalase on the phenylephrine-induced response as well as its enhancing effect
of acetylcholine-induced relaxation. In SHR VSMCs, angiotensin II increased TLR4 mRNA levels, and losartan reduced that
increase. CLI-095, a TLR4 inhibitor, mitigated the increases in NAD(P)H oxidase activity, superoxide anion production,
migration and proliferation that were induced by angiotensin II. In conclusion, TLR4 pathway activation due to increased
RAS activity is involved in hypertension, and by inducing oxidative stress, this pathway contributes to the endothelial
dysfunction associated with this pathology. These results suggest that TLR4 and innate immunity may play a role in
hypertension and its associated end-organ damage.
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Introduction
Hypertension has been generally associated with structural and
functional vascular alterations, and both endothelial dysfunction
and increased vasoconstrictor responses are important features of
this pathology. The reduced nitric oxide (NO) bioavailability
caused by increased reactive oxygen species (ROS) production
would explain these vascular alterations. In this context, in recent
years, it has been proposed that low-grade inflammation plays a
key role in the development and progression of hypertension [1–
4]. Indeed, in hypertension, increases in the plasma levels of
proinflammatory cytokines [1], in the ROS production [5,6] and
in the vascular responses to lipopolysaccharide (LPS) [7–9] have
been observed. It is worth noting that inflammation also induces
endothelial dysfunction in humans and animals [9,10]. Increased
activation of the renin-angiotensin system (RAS) seems to be
associated with the inflammatory state observed in hypertension,
as well as with its associated vascular alterations [1,5,11,12].
Angiotensin II (Ang II), the effector peptide of RAS, is able to
induce Toll-like Receptor 4 (TLR4), and it seems that TLR4-
dependent signaling pathway contributes to the proinflammatory
effects of this humoral factor [13–19].
TLRs belong to a large family of pattern recognition receptors
that play important roles in mammalian defense systems against
invading microorganisms. Among then, TLR4 is expressed on the
surface of several cell types, including endothelial and vascular
smooth muscle cells (VSMCs). It recognizes and responds against
LPS, the main component of the cell wall of Gram-negative
bacteria, as well as other non-infectious compounds, such as the
products of tissue death and/or damage (DAMP), heat shock
proteins (Hsp), high-mobility group box 1 (HMGB1) protein,
fibronectin, heparan sulfate and fibrinogen. After activation,
TLR4 can initiate the innate and, subsequently, the adaptive
immunity; both mechanisms are responsible for the inflammatory
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response [20,21]. It has also been shown that upon TLR4
activation, LPS produces ROS such as superoxide anion and
hydrogen peroxide [22–25], which also contribute to the
inflammatory response.
The roles of the TLR4 signaling pathway in the processes
underlying inflammatory vascular diseases including atherosclero-
sis [14], diabetes [26–28] or pre-eclampsia [29,30] have been
reported. While several studies have addressed the contribution of
adaptive immunity to the pathophysiology of hypertension, there
are few studies regarding the role of the innate immune system in
the context of this pathology [31–33]. Therefore, the aim of this
study was to investigate whether TLR4 activation, due to
increased RAS activity, contributes to hypertension and the
functional vascular alterations observed in this pathology. The
specific objectives were to investigate the following: 1) the
alteration of TLR4 expression in hypertension and the contribu-
tion of Ang II to this alteration; 2) the role of TLR4 in
hypertension occurrence, as well as in the associated vascular
function alterations; and 3) the involvement of the TLR4-activated
ROS production in the vascular dysfunction associated to this
pathology.
Materials and Methods
Ethics statement and Animals
All experiments were approved by the Ethical Commission for
the Use of Animals of Universidade Federal do Espı´rito Santo,
Brazil (CEUA-UFES 042/2013) and by the Ethical Committee of
Research of the Universidad Auto´noma de Madrid, Spain (CEI-
UAM 31-759). This study was carried out in strict accordance with
the recommendations for biomedical research as stated by the
Brazilian Societies of Experimental Biology, the guidelines for
ethical care of experimental animals of the European Community,
the current Spanish and European laws (RD 223/88 MAPA and
609/86), and the International Guiding Principles for Biomedical
Research Involving Animals.
Adults male spontaneously hypertensive (SHRs) and Wistar rats
were used for these studies. Rats were housed under a 12 h light/
12 h dark cycle, they had free access to water and were fed a
standard rat chow ad libitum. In one set of experiments, we
analyzed if hypertension alters TLR4 expression and its depen-
dence on RAS activity. For this, we used Wistar rats and SHRs
untreated and treated with the AT1 receptor antagonist losartan
(15 mg/kg?day in the drinking water, 12 weeks; generously
supplied by Merck & Co., Inc., Rahway, NJ, USA). Systolic
arterial pressure was measured by tail plethysmography.
In another set of experiments, we investigated whether the
TLR4 receptor plays a role in the occurrence of hypertension and
Figure 1. Ang II contributes to the increased TLR4 mRNA levels observed in SHRs. (A) TLR4 mRNA levels in aortic segments from Wistar,
SHRs and SHRs treated with losartan (15 mg/kg?day in the drinking water, 12 weeks). (B) TLR4 mRNA levels in VSMCs from Wistar rats and SHRs. (C)
Representative fluorescent confocal photomicrographs of TLR4 immunolocalization in aortic segments from Wistar and SHRs. Image size
2386238 mm. The results (mean6SEM) are expressed as the relative expression compared with the Wistar rats. *P,0.05 vs. Wistar, #P,0.05 vs. SHR
using the Mann-Whitney nonparametric test. n = 6–7.
doi:10.1371/journal.pone.0104020.g001
TLR4 and Endothelial Dysfunction in Hypertension
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e104020
the associated vascular alterations. For this, we used SHRs
(258.5610.9 g, n = 10) treated with an anti-TLR4 antibody (rat
monoclonal IgG2a, 1 mg/day saline-diluted, intraperitoneal injec-
tion, 15 days; sc-13591, Santa Cruz Biotechnology Inc., Dallas,
TX, USA) and Wistar rats (272.1615.7 g, n = 9) and SHRs
(245.9612.5 g, n = 9) treated with a non-specific IgG (IgG2a,
Figure 2. TLR4 inhibition reduces blood pressure and heart rate in hypertensive rats. (A) Systolic blood pressure (SBP), (B) diastolic blood
pressure (DBP), (C) mean blood pressure (MBP) and (D) heart rate (HR) in Wistar and SHRs treated with a non-specific IgG (1 mg/day, 15 days) and
SHRs treated with anti-TLR4 antibody (1 mg/day, 15 days). The results represent the mean6SEM. *P,0.05 vs Wistar, #P,0.05 vs. SHR using one way
ANOVA and Bonferroni post-test. n = 8–9.
doi:10.1371/journal.pone.0104020.g002
Figure 3. TLR4 inhibition reduces phenylephrine-elicited vasoconstriction and increases acetylcholine-elicited vasodilation in SHR
aortas. Concentration-response curves to phenylephrine (A) and acetylcholine (B) in endothelium-intact aortic segments from Wistar and SHRs
treated with a non-specific IgG (1 mg/day, 15 days) and SHRs treated with anti-TLR4 antibody (1 mg/day, 15 days). The results are the mean6SEM.
*P,0.05 vs Wistar, #P,0.05 vs. SHR using two-way ANOVA and Bonferroni post-test. The number of animals used is shown in parentheses.
doi:10.1371/journal.pone.0104020.g003
TLR4 and Endothelial Dysfunction in Hypertension
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1 mg/day, saline-diluted, intraperitoneal injection, 15 days; sc-
2026, Santa Cruz Biotechnology Inc.) to rule out non-specific
effects of the anti-TLR4 antibody treatment [32]. Hemodynamic
parameters and vascular function in aortic rings were evaluated.
To further elucidate the role of TLR4 in the Ang II effects, cell
culture experiments using VSMCs from Wistar and SHR were
used.
Rats were euthanized by CO2, and all efforts were made to
minimize suffering. Then, the aortas were removed and placed in
cold (4uC) Krebs-Henseleit solution (KHS) (115 mM NaCl,
25 mM NaHCO3, 4.7 mM KCl, 1.2 mM MgSO4.7H2O,
2.5 mM CaCl2, 1.2 mM KH2PO4, 11.1 mM glucose, and
0.01 mM Na2EDTA) aerated with a 95% O2-5% CO2 mixture
(pH = 7.4). Aortic segments were dissected free of fat and
connective tissue and maintained in KHS. Segments used for
gene expression studies were immediately frozen in liquid nitrogen
and kept at 270uC until the day of the experiment. The hearts
were removed to assess cardiac hypertrophy. For this, the ratio
between the heart dry weight and the length of the tibia was
calculated.
Figure 4. TLR4 inhibition increases endothelial modulation of vasoconstrictor responses. Concentration-response curves to
phenylephrine in intact (E+) and endothelium denuded (E2) aortic segments from (A) Wistar and (B) SHRs treated with a non-specific IgG (1 mg/
day, 15 days) and (C) SHRs treated with anti-TLR4 antibody (1 mg/day, 15 days). (D) Differences in the area under the concentration-response curve
(dAUC) in the E– and E+ segments; AUC was calculated from the individual curve plots; the differences are expressed as a percentage of the AUC for
the corresponding control situation. (E) Contractile response to L-NAME (100 mM) after phenylephrine (1 mM) contraction in segments from Wistar
and SHRs treated with a non-specific IgG and SHRs treated with anti-TLR4 antibody; the results are expressed as the percentage of the previous
contraction induced by phenylephrine. The results are the mean6SEM. *P,0.05 vs. E+ or vs. Wistar, #P,0.05 vs. SHR using two-way ANOVA and
Bonferroni post-test. The number of animals used is shown in parentheses.
doi:10.1371/journal.pone.0104020.g004
TLR4 and Endothelial Dysfunction in Hypertension
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Hemodynamic parameters
At the end of the treatment, body weight was recorded and the
rats were anesthetized with urethane (4 g/kg of body weight,
intraperitoneal injections). The right coronary artery was cannu-
lated with a heparinized polyethylene catheter (PE-50) and
connected to a data acquisition system with pressure transducers
(TSD 104A, Biopac Systems, Inc., Goleta, CA, USA) to measure
hemodynamic parameters. Following an adaptation period of
30 min, systolic, diastolic, mean blood pressure and heart rate
(SBP, DBP, MBP and HR, respectively) measurements were
recorded.
Vascular function
Vascular function was studied in aortic segments by isometric
tension recording using an isometric force transducer (TSD 125C)
connected to an acquisition system (Biopac Systems, Inc.).
Segments were initially exposed to 75 mM KCl to test their
functional integrity, and the presence of endothelium was
confirmed by the effect of 10 mM acetylcholine in segments that
previously contracted with 1 mM phenylephrine. After a washout
period, a single concentration-response curve to phenylephrine
(0.1 nM–0.3 mM) or acetylcholine (0.01 nM–0.3 mM) was per-
formed. Thus, parallel experiments in different aortic segments
from the same animal were performed in the absence (control) and
the presence of the NAD(P)H oxidase inhibitor apocynin (30 mM),
Figure 5. TLR4 inhibition abolishes the inhibitory effect of antioxidants on phenylephrine-induced contraction. Concentration-
response curves to phenylephrine in aortic segments from Wistar and SHRs treated with a non-specific IgG (1 mg/day, 15 days) and SHRs treated with
anti-TLR4 antibody (1 mg/day, 15 days) in the absence and presence of (A) tiron (1 mM), (B) apocynin (30 mM) and (C) catalase (1000 U/ml). Control
curves were the same in the different situation of the three experimental groups. The results are the mean6SEM. *P,0.05 vs. SHR using two-way
ANOVA and Bonferroni post-test. The number of animals used is shown in parentheses.
doi:10.1371/journal.pone.0104020.g005
TLR4 and Endothelial Dysfunction in Hypertension
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the superoxide anion scavenger 4, 5-dihydroxy-1, 3-benzene-
disulphonic acid (tiron, 1 mM) and the hydrogen peroxide
detoxificant catalase (1000 U/ml). These drugs were administered
30 min prior to incubation with phenylephrine or acetylcholine.
The influence of endothelium on the response to phenylephrine
was investigated after mechanical removal of this vascular
component by rubbing the lumen with a needle. The absence of
endothelium was confirmed by the inability of 10 mM acetylcho-
line to produce relaxation. To evaluate the NO component of the
phenylephrine responses, the aortic rings were half-maximally pre-
contracted with 1 mM phenylephrine for 30 min; then, a non-
selective inhibitor of NO synthesis, NG-nitro-L-arginine methyl
ester (L-NAME, 100 mM), was added for 45 min. The results of
Figure 6. TLR4 inhibition abolishes the enhancing effect of antioxidants on acetylcholine-induced vasodilation. Concentration-
response curves to acetylcholine in aortic segments Wistar and SHRs treated with a non-specific IgG (1 mg/day, 15 days) and SHRs treated with anti-
TLR4 antibody (1 mg/day, 15 days) in the absence and presence of (A) tiron (1 mM), (B) apocynin (30 mM) and (C) catalase (1000 U/ml). Control curves
were the same in the different situation of the three experimental groups. The results are the mean6SEM. *P,0.05 vs. SHR using two-way ANOVA
and Bonferroni post-test. The number of animals used is shown in parentheses.
doi:10.1371/journal.pone.0104020.g006
TLR4 and Endothelial Dysfunction in Hypertension
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the additional tone caused by L-NAME were expressed as the %
of the previous contraction elicited by phenylephrine [34].
Immunofluorescence
TLR4 was immunolocalized as described [12]. Briefly, frozen
transverse sections (14 mm) were cut on to gelatin coated slides and
air-dried for at least 60 min. After blockade, sections were
incubated with a polyclonal antibody against TLR4 (1:100, Santa
Cruz Biotechnology, Inc.) in PBS containing 2% bovine serum
albumin (BSA, Sigma Chemical Co.) for 1 h at 37uC in a
humidified chamber. After washing, rings were incubated with the
secondary antibody, a goat anti-rat (1:200) IgG labeled with alexa
fluor-546 dye (Molecular Probes Inc., Eugene, OR, USA) for 1 h
at 37uC in a humid box. After washing, immunofluorescent signals
were viewed using an inverted Leica TCS SP2 confocal laser-
scanning microscope with oil immersion lens (x40). Alexa Fluor-
labeled antibody was visualized by excitation at 546 nm and
detection at 550–650 nm. The specificity of the immunostaining
was evaluated by omission of the primary antibody and processed
as above. Under these conditions, no staining was observed in the
vessel wall. Nuclei were stained with 0.01 mg/ml DAPI (Molec-
ular Probes Life Technologies) and visualized with excitation/
emission wavelengths of 358/461 nm.
Cell Culture
To obtain primary cultures of VSMCs, thoracic aortas from
SHRs or Wistar rats were aseptically removed, cleaned of fat tissue
and blood cells and placed in cold Dulbecco’s modified Eagle’s
medium (DMEM) (Sigma Chemical Co., St. Louis, Mo, USA)
containing 0.1% BSA, 200 U/ml penicillin and 200 mg/ml
streptomycin. The aortas were digested in the same medium
containing 2 mg/ml collagenase type II (Worthington, Lakewood,
NJ, USA) and incubated for 30 min at 37uC in a humidified
atmosphere of CO2 (5%). After the adventitia was carefully
removed, VSMCs were obtained using the explant method [35].
Cells were identified as VSMCs by morphological and growth
characteristics and by positive immunocytochemical staining with
a specific monoclonal anti-a-actin antibody (Sigma Chemical Co.).
For experiments, cells from passages 2 to 5 were rendered
quiescent by incubation in DMEM containing 0.2% FBS for 24 h.
The cells were stimulated with 100 nM Ang II (for the times
indicated in the results section), with or without pretreatment for
1 h with the TLR4 inhibitor CLI-095 (1 mM). The specificity of
CLI-095 was confirmed by its capacity to abolish the induction of
COX-2 expression in VSMCs following exposure to LPS (data not
shown).
Quantitative PCR real time (qRT-PCR) assay
TLR4, NOX-1, NOX-2, NOX-4 and p22phox mRNA levels
were determined in the aortic segments and/or VSMCs by qRT-
PCR. Total RNA was obtained using the TRI Reagent (Sigma
Chemical Co.), according to the manufacturer’s recommenda-
tions, and was reverse-transcribed using the High Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA, USA). PCR was
performed using the fluorescent dye SyBR Green (iTaq FAST
SyBR Green Supermix with ROX, Bio-Rad Laboratories,
Hercules, CA, USA) or using Taqman Gene Expression Assays
(NOX-1: Rn00586652_m1; NOX-4: Rn00585380_m1, Applied
Biosystems). The primer sequences used are: TLR4 (FW:
TGTGCCTTCAAAACATGACTGG, RV: CTCCCAAGAT-
CAACCGATGG); p22phox (FW: GGACAGAAGTACCT-
GACCGC, RV: GATGGTGGCCAGCAGGAAG); NOX-2
(FW: CCAGTGAAGATGTGTTCAGCT, RV: GCACAGC-
CAGTAGAAGTAGAT). Cyclophilin D (Rn01458749_g1, Ap-
plied Biosystems) and b2-microglobulin (Rn00560865_m1, Ap-
plied Biosystems) were used as normalizing internal controls. All
PCRs were performed in duplicate. qRT-PCR was carried out in
an ABI PRISM 7000 Sequence Detection System (Applied
Biosystems, from the Centro de Apoyo Tecnolo´gico of URJC)
using the following conditions: 2 min at 50uC; 10 min at 95uC;
and 40 cycles of 15 s at 95uC and 1 min at 60uC. At the end of the
SyBR Green PCR, a final stage with a melting curve analysis was
added to show the specificity of the product. To calculate the
relative index of gene expression, we employed the 22DDCt method
using the untreated samples for calibration.
Detection of ROS
The oxidative fluorescent dye dihydroethidium (DHE) was used
to evaluate in situ superoxide anion production in VSMCs [35].
Hydroethidine freely permeates cells, and in the presence of
superoxide anions it is oxidized to ethidium bromide, which is
trapped by intercalation with DNA. Ethidium bromide is excited
at 546 nm and has an emission wavelength of 610 nm. Briefly,
VSMCs were plated onto glass coverslips placed in 6-well plates
Figure 7. Ang II upregulates TLR4 expression in SHR VSMCs via the AT1 receptors. (A) Effect of Ang II (100 nM, 15 min-3 h) on TLR4 mRNA
levels in SHR VSMCs. (B) Effect of Ang II (2 h) on TLR4 mRNA levels in the absence and the presence of losartan (10 mM, 1 h). The results (mean6SEM)
are expressed as relative expression compared with control. *P,0.05 vs Control, #P,0.05 vs Ang II by Student’s t-test. n = 4–5.
doi:10.1371/journal.pone.0104020.g007
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and cultured as described above. Subconfluent cells were
stimulated with 100 nM Ang II for 2 h in the absence or presence
of 1 mM CLI-095, which was added 1 h prior Ang II. The cells
were then incubated with 10 mM DHE in cell culture medium for
30 min at 37uC. The images were then acquired using a
fluorescence microscope (Nikon Eclipse T300, objective 620,
Nikon Corporation, Tokyo, Japan), captured using a digital spot
camera (Diagnostic, Spectra Services, Ontario, NY, USA) and
processed using the Metamorph image analysis software (Molec-
ular Devices Corp., Downingtown, PA, USA). Non-stimulated
VSMCs were imaged daily in parallel, using the same image
settings throughout the course of the study. DHE fluorescence was
Figure 8. TLR4 inhibition reduces Ang II-induced NAD(P)H oxidase activity and O2
2 production in VSMC from SHR. Effects of CLI-095
(1 mM, 1 h) on Ang II (100 nM, 2 h)-induced (A) NOX-1, NOX-4 and p22phox mRNA levels, (B) NAD(P)H oxidase activity and (C) O22N production in SHR
VSMCs. The results (mean6SEM) are expressed as relative values compared with the control. *P,0.05 vs. Control, #P,0.05 vs. Ang II using Student’s
t-test or the Mann-Whitney nonparametric test. n = 4–6.
doi:10.1371/journal.pone.0104020.g008
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quantified in individual cell nuclei (10–20 nuclei/image/experi-
mental condition). At least 5 independent experiments were
performed. Then, we expressed the effects of the different drugs as
fold increases over the control.
NAD(P)H oxidase activity
The superoxide anion generated by NAD(P)H oxidase activity
was determined using a chemiluminescence assay using 5 mM
lucigenin and 100 mM NAD(P)H. VSMCs treated as described for
the ROS detection experiments were homogenized in a lysis buffer
(50 mM KH2PO4, 1 mM ethylene glycol tetraacetic acid,
150 mM sucrose, pH = 7.4). The reaction was initiated with the
addition of a mixture of lucigenin and NAD(P)H to the protein
sample in a final volume of 300 ml. Chemiluminescence was
determined every 2.4 s for 5 min in a plate luminometer (Auto-
Lumat LB 953, Berthold Technologies GmbH & Co. KG, Bad
Wildbad, Germany). A buffer blank was subtracted from each
reading, and the value of the area under the curve was used to
quantify chemiluminescence. The data obtained (counts/s) were
expressed as fold increases over the control situation.
In vitro wound healing assay
To verify the role of TLR4 in Ang II-induced migration, a
wound healing assay was performed. For this, the cells were seeded
and cultured to confluence in a 24-well plate. Then, the cells were
switched to serum-free medium for 24 h before the initiation of the
experiments. A wound was made with a P10 pipette tip (CRP,
with a filter). The medium was changed twice (5 ml/well) to wash
away any cell debris remaining in the wound area. A line was
drawn through the center of the wells, perpendicular to the
wound. A picture was taken at time zero at the site of intersection
of the line and the wound. Then, the cells were treated for 1 h with
1 mM CLI-095, followed by 100 nM Ang II. At 24 h, we took a
picture in the same location. Adobe Photoshop CS2 was used to
determine the area of wound closure compared to time 0 for the
stimulus and with respect to the control situation.
Cell proliferation assay
Cell proliferation was assessed using the CellTiter 96 Non-
Radioactive Cell Proliferation Assay (Promega Corporation,
Madison, WI, USA). For this, VSMCs were seeded in 96-well
plates (206103 cells/well) in DMEM and were allowed to attach
for 24–36 h. Then, the cells were switched to serum-free medium
for 24 h. After this, cells were treated with 1 mM CLI-095 for 1 h,
followed by 100 nM Ang II for 24 h. The proliferative response
was quantified by adding MTS tetrazolium solution (20 ml/well).
After 2–3 h of incubation, absorbance was measured at 490 nm
using a microplate reader (ASYS Hitech GmbH, Eugendorf,
Austria). Different assays were performed in triplicate.
Drugs and reagents
l-phenylephrine hydrochloride, acetylcholine chloride, tiron,
catalase, apocynin, lucigenin, salts and other reagents were
purchased from Sigma Chemical Co. and Merck (Darmstadt,
Germany). DHE, streptomycin and penicillin were obtained from
Invitrogen (Carslbad, CA, USA), and CLI-095 was obtained from
Invivogen (San Diego, CA, USA). All drugs were dissolved in
distilled water, except for CLI-095, which was dissolved in
Figure 9. TLR4 inhibition reduces Ang II-induced cell migration and proliferation. (A) Wound healing assay showing SHR VSMC migration
in response to Ang II (100 nM, 24 h) and effect of CLI-095 (1 mM, 1 h). (B) Effect of CLI-095 on Ang II-induced proliferation. The results (mean6SEM)
are expressed as relative values compared with the control. *P,0.05 vs Control, #P,0.05 vs. Ang II using Student’s t-test. n = 5.
doi:10.1371/journal.pone.0104020.g009
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dimethyl sulfoxide (DMSO); 10 ml of DMSO did not have any
effect on VSMCs.
Statistical analyses
Vasoconstrictor responses induced by phenylephrine were
expressed as the % of the tone generated by 75 mM KCl.
Vasodilator responses induced by acetylcholine were expressed as
the % of the previous tone in each case. The maximum response
(Emax) and pD2 values were calculated by non-linear regression
analysis of each individual concentration-response curve using
GraphPad Prism Software. To compare the effect of endothelium
removal on the response to phenylephrine in segments from the
three groups, the results are expressed as the differences of areas
under the concentration-response curves (dAUC) in the control
and experimental situations. AUCs were calculated from the
individual concentration-response curve plots using a computer
program (GraphPad Prism Software, San Diego, CA, USA); the
differences were expressed as the % of the AUC of the
corresponding control situation.
The results are expressed as the mean6SEM (standard error of
the mean) of the number of animals or the number of different
cultures used in each experiment; differences were analyzed using
Students t-test or one- or two-way analyses of variance (ANOVA),
followed by the Bonferroni post hoc test, or Mann-Whitney
nonparametric test by using GraphPad Prism Software. Differ-
ences were considered statistically significant at P,0.05.
Results
Angiotensin II contributes to increased vascular TLR4
gene expression in SHRs
TLR4 mRNA expression was greater in aortic segments from
SHRs when compared with those from Wistar rats; this greater
expression was reduced after treatment of SHRs with the AT1
receptor antagonist losartan (Fig. 1A), which suggests that Ang II
contributes to this increased expression. Similarly, TLR4 mRNA
levels were greater in VSMCs from SHRs than from Wistar rats
(Fig. 1B).
Immunofluorescence experiments confirm the greater expres-
sion of TLR4 in aorta from SHR when compared with Wistar
rats; this receptor was localized in the three layers of the vascular
wall (Fig. 1C).
TLR4 inhibition reduces blood pressure and heart rate in
hypertensive rats
At the end of the treatment, body weight (Wistar:
322.8610.4 g, n = 7; SHR: 289.867.6 g, n = 9; anti-TLR4 SHRs:
281.5610.7 g, n = 10) and the tibia length (Wistar: 3.860.1; SHR:
3.460.1; anti-TLR4 SHRs: 3.260.1 cm) was similar (P.0.05) in
the three animal groups. The heart weight:tibia length ratio was
greater in SHRs (0.34660.022) as compared with Wistar rats
(0.29460.009), although the differences did not reach statistical
significance (P = 0.068); treatment of SHR with anti-TLR4
antibody did not affect this ratio (0.34660.009, P.0.05).
As expected, SHRs have greater levels of SBP, DBP, MBP and
HR than Wistar rats (Fig. 2A–D). Anti-TLR4 antibody treatment
of SHR lowered the SBP, DBP and MBP in SHRs (Fig. 2A–C)
compared with the controls. Additionally, the HR also decreased
with treatment (Fig. 2D).
TLR4 inhibition reduces phenylephrine-elicited
vasoconstriction and increases acetylcholine-elicited
vasodilation in SHR aortas
The maximum response induced by 75 mM KCl was similar in
the aortic rings from both Wistar (1.8760.01 g; n = 8) and SHRs
(1.9260.08 g, n = 9; P.0.05). Treatment of SHRs with the anti-
TLR4 antibody did not modify KCl response (1.7060.01 g,
n = 10; P.0.05). The contraction induced by phenylephrine was
greater in aortic segments from SHR when compared with Wistar
rats (pD2 SHR: 6.6960.07 vs. Wistar: 6.5460.11, P.0.05; Emax
SHR: 135.768.0% vs. Wistar: 100.369.5%, P,0.05; Fig. 3A);
however, after anti-TLR4 antibody treatment of SHRs the
phenylephrine-induced responses were lower (pD2 SHR anti-
TLR4: 6.2260.12, P,0.05 vs. SHR; Emax SHR anti-TLR4:
105.2613.4%, P,0.05 vs. SHR; Fig. 3A). Furthermore, endo-
thelium-dependent relaxation to acetylcholine was lower in SHRs
(pD2 SHR: 7.2560.19 vs. Wistar: 7.4660.16, P.0.05; Emax
SHR: 73.264.7% vs. Wistar: 95.362.4%, P,0.05; Fig. 3B),
being these responses increased by the anti-TLR4 antibody
treatment (pD2: 8.1060.14, P,0.05; Emax: 89.263.3%, P,
0.05; Fig. 3B).
To evaluate the influence of endothelium in the response to
phenylephrine, this layer was mechanically removed. In these
conditions, the response to phenylephrine was increased in the
three groups (Fig. 4A–C); however, this increase was smaller in
SHRs, as shown by the analysis of dAUC values, while the anti-
TLR4 antibody treatment restored this increase (Fig. 4D). These
results suggest that hypertension reduces the endothelial modula-
tion of phenylephrine responses and that the treatment reestab-
lishes this modulation. The tension developed by the NO synthase
antagonist L-NAME (100 mM) after phenylephrine contraction
was lower in SHRs when compared with Wistar rats, and this
contraction was increased after treatment of SHRs with the anti-
TLR4 antibody (Fig. 4E). These results indirectly suggest that
treatment significantly increases NO production. Altogether, these
results allow us to propose that the anti-TLR4 antibody treatment
improves endothelial dysfunction in SHRs, and this improvement
most likely occurs by increasing NO bioavailability.
TLR4 inhibition decreases the contribution of oxidative
stress to the vasoconstrictor and vasodilator responses in
aortas from hypertensive rats
Endothelial dysfunction accompanying hypertension is fre-
quently associated with reduction in NO bioavailability caused
by increased ROS production, among other mechanisms.
Therefore, we analyzed the effect of anti-TLR4 antibody
treatment on the contribution of ROS to vascular function. The
superoxide anion scavenger tiron, the NAD(P)H oxidase inhibitor
apocynin and the hydrogen peroxide detoxificant catalase did not
affect phenylephrine-induced contraction in Wistar rats, while the
three drugs reduced those responses in SHRs (Fig. 5A–C).
Treatment with the anti-TLR4 antibody completely abolished
the inhibitory effect of the three antioxidants analyzed (Fig. 5A–
C).
On the other hand, tiron, apocynin and catalase did not affect
acetylcholine-induced relaxation in Wistar rats but increased that
response in SHRs; after anti-TLR4 antibody treatment of SHRs
the enhancing effect of the three compounds was abolished
(Fig. 6A–C). Altogether, these results suggest that TLR4 in-
creased oxidative stress and this would contribute to the impaired
vascular function observed in aortas from hypertensive rats. In an
attempt to investigate if these effects of TLR4 are related to the
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increased RAS activity in SHRs, the following experiments were
carried out using cultured VSMCs stimulated with Ang II.
Angiotensin II increases oxidative stress in VSMCs
through TLR4 activation
In SHR VSMCs, Ang II (100 nM) incubation increased TLR4
mRNA levels from 15 min to 3 h (Fig. 7A), and this effect was
reduced by preincubation with losartan (1 mM, Fig. 7B), which
indicates the involvement of AT1 receptors in such induction.
It has been widely shown that Ang II increases ROS production
thus contributing to the inflammatory process associated with
hypertension [1,6,36]. Accordingly, in SHR VSMCs, Ang II
(100 nM, 2 h) treatment increased NOX-1 and NOX-4 mRNA
levels, while p22phox mRNA levels were unaffected (Fig. 8A);
NOX-2 mRNA levels were scarcely detected (results not shown).
In addition, Ang II also increased NAD(P)H oxidase activity and
the subsequent superoxide anion production (Fig. 8B, C). The
TLR4 antagonist CLI-095 did not affect NOX-1 mRNA levels;
however, CLI-095 mitigated the increased NOX-4 mRNA levels,
NAD(P)H activity and superoxide anion production induced by
Ang II (Fig. 8A–C), which indicates a role for TLR4 in the
increased oxidative stress induced by Ang II.
The ability of Ang II to induce cell migration and proliferation
is well known [37]. The TLR4 inhibitor CLI-095 also reduced the
increased cell migration and proliferation induced by Ang II
(100 nM, 24 h, Fig. 9A, B), which suggests that TLR4 contrib-
utes to these effects.
In SHR VSMCs, the TLR4 antagonist CLI-095 alone did not
modify any parameter studied (results not shown).
Discussion
The results of this study suggest that increased expression of
TLR4, which is associated with increased RAS activity, contrib-
utes to the occurrence of hypertension. Additionally, this increased
TLR4 expression is also involved in the previously described
increased oxidative stress that most likely contributes to the
endothelial dysfunction observed in hypertension.
TLR4 is expressed on the surface of different cell types
including endothelial cells and VSMCs, and is involved in the
recognition of and response to LPS, although many non-infectious
endogenous TLR4 ligands also exist [4,20,21]. There is evidence
regarding a role for the TLR4 signaling pathway and the innate
immune response in the development of cardiovascular patholo-
gies with an inflammatory component such as atherosclerosis [14],
diabetes [26–28] and pre-eclampsia [29,30]. Hypertension has
also been considered as a low-grade inflammatory disease, and
growing evidence shows that the immune system is involved in the
pathophysiology of hypertension [2–4]. In the present study, we
found that TLR4 expression was increased in the three layers of
the vascular wall of aortic segments as well as in cultured VSMCs
from SHRs compared with Wistar rats, suggesting that TLR4
from the endothelial and smooth muscle cells, and even from the
adventitia, might contribute to the effects discussed below. The
results are similar to that found in mesenteric resistance arteries
from SHR [32] as well as in cardiomyocytes from both adults
SHR and L-NAME-induced hypertensive rats [31]. Additionally,
in peripheral monocytes from nondiabetic hypertensive patients,
increased TLR4 gene expression has also been reported;
antihypertensive treatment reduces that expression with a
significantly association with the systolic and diastolic blood
pressure reduction [38]. Increased TLR4 levels in SHRs can
explain the enhanced vascular responses to LPS that we previously
observed [7–9]. Furthermore, TLR4 expression seems to be
associated with the development/maintenance of hypertension
because treatment of SHRs with an anti-TLR4 antibody for 2
weeks reduced blood pressure, as previously described [32].
Accordingly, a recent report has shown that L-NAME failed to
induce hypertension in TLR42/2 mice [33]. Moreover, after the
use of a neutralizing antibody in vivo in SHRs, the heart rate was
also reduced suggesting that the cardiac effects of TLR4 can
contribute to the hypertensive action of this pathway. In this sense,
it has been described that activation of the TLR4 in the brainstem
via AT1R contributes to the sympathoexcitation drive in heart
failure [39] and recently Dange et al. [40] has shown that brain
TLR4 blockade improves cardiac function in Ang II-induced
hypertensive rats.
RAS contributes to the vascular alterations associated with
hypertension via its proinflammatory activity in the vascular wall,
including the production of ROS, cytokines and prostanoids
[1,6,36]. Furthermore, Ang II is able to induce the inflammatory
response via the TLR4 pathway [13–19]; in addition, AT1
receptor blockers (ARBs) reduce the LPS-induced innnate
immune response [41–43] and protect against myocardial
ischemia-reperfusion injury through the TLR4/NF-kB signaling
pathway [44]. Accordingly, we found that Ang II increased TLR4
mRNA levels in SHR VSMCs via the AT1 receptors, and
treatment of SHRs with losartan in vivo decreased the increased
TLR4 levels found in this strain. These results suggest that the
increased RAS activity observed in hypertension contributes to the
increased TLR4 levels.
Hypertension is associated with functional vascular alterations
such as endothelial dysfunction with impaired endothelium-
dependent relaxations and increased vasoconstrictor responses.
Endothelial dysfunction is a prognostic factor for cardiovascular
events in patients with essential hypertension [45]. Our results
demonstrate that the anti-TLR4 antibody treatment improved the
vasodilator responses to acetylcholine in SHRs. Additionally, the
anti-TLR4 antibody reduced vasoconstrictor responses to phen-
ylephrine, in agreement with results obtained in mesenteric
resistance arteries [32]. Moreover, the increased phenylephrine
response after endothelial denudation was greater in anti-TLR4
antibody-treated SHRs. Altogether, this study suggests for the first
time, to the best of our knowledge, that TLR4 contributes to the
endothelial dysfunction observed in hypertension. In keeping with
this, our group and others have previously shown that LPS
administration induces endothelial dysfunction in both peripheral
[46,47] and cerebral arteries [9]. Additionally, Liang et al. [48]
reported that the in vivo and in vitro administration of LPS causes
endothelial dysfunction in the arteries of wild-type mice, but not
those of TLR4-mutated mice. The proposed role of TLR4 in
endothelial dysfunction and the above mentioned increased TLR4
expression found in hypertensive animals can explain the greater
impairment of bradykinin-induced relaxation elicited by LPS that
was observed in the middle cerebral arteries of hypertensive rats
[9].
One of the mechanisms that explain the endothelial dysfunction
induced by TLR4 activation is the reduction of NO contribution
to vascular responses. Accordingly, anti-TLR4 treatment im-
proved endothelium-dependent relaxation, which in aorta is
dependent on NO [49]; in addition, the L-NAME-induced
contraction was greater in SHR aortic segments after anti-TLR4
antibody treatment, suggesting that this treatment might increase
NO bioavailability. Augmented oxidative stress is one of the most
generally accepted mechanism to explain the reduced NO
bioavailability in hypertension [50,51]. There is evidence indicat-
ing that upon TLR4 activation, LPS increases the generation of
ROS, such as O2
2 and H2O2, from NAD(P)H oxidase, and these
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ROS are involved in NF-kB activation and the subsequent
expression of proinflammatory cytokines [22–25]. In the present
study we found that the effect of antioxidants (apocynin, catalase
and tiron) on both vascular contraction and relaxation disap-
peared after anti-TLR4 antibody treatment, suggesting that TLR4
contributes to the increased ROS production and endothelial
dysfunction observed in hypertension. Accordingly, in obesity- and
diabetes-associated endothelial dysfunction by increasing oxidative
stress TLR4 plays a key role [48]. Recently, it was proposed that
the greater ROS production caused by DAMPs release in L-
NAME-induced hypertensive mice contributes to the vascular
alterations found in this model [33]. TLR4 could also contribute
to endothelial dysfunction by reducing NO production. Indeed, in
cardiac microvascular endothelial cells, a reduction of eNOS
expression and NO production via TLR4 signaling has been
described under hypoxia/reoxygenation conditions [52]. Howev-
er, we cannot discard COX-dependent mechanisms associated
with TLR4 activation that might contribute to the vascular
dysfunction associated with hypertension [32].
RAS plays an important role in increasing the oxidative stress
present in hypertension [1,5,6,12,36]. In SHR VSMCs, the TLR4
antagonist mitigated the increased NOX-4 expression, NAD(P)H
oxidase activity and superoxide anion production induced by Ang
II. These results support the contribution of RAS-induced TLR4
in the oxidative stress observed in hypertension. Some authors
have also described the role of TLR4 in the Ang II effects
mediated by ROS production. Thus, after Ang II release,
osteocalcin activates PKC/TLR4/ROS/COX-2, which mediates
the transformation of fibroblasts to myofibroblasts [19]. Addition-
ally, TLR4/MyD88-mediated oxidative stress is involved in Ang
II-induced mesangial cell apoptosis [17].
Ang II induces VSMC proliferation and migration that
contribute to the progression of many vascular diseases, including
hypertension [37]. Yuen et al. [19] have shown that the Ang II-
induced migration of rat adventitial fibroblasts is mediated by
TLR4 activation. Additionally, TLR4 contributes to the increased
proliferation and migration induced by other stimuli [53,54].
Accordingly, the increased cell proliferation and migration
induced by Ang II was reversed by TLR4 antagonists, thus
suggesting that increased TLR4 expression is functionally associ-
ated with structural alterations that can also contribute to
hypertension.
In conclusion, this study demonstrates, for the first time, that the
increased RAS activity observed in hypertension stimulates the
TLR4 pathway, contributing to the occurrence of hypertension.
Additionally, by inducing oxidative stress, TLR4 leads to the
endothelial dysfunction that is characteristic of this pathology. In
recent years, several studies had demonstrated the role of adaptive
immunity in the pathogenesis of hypertension [2,3]. Our results
also suggest the impact of the TLR4 signaling pathway on the
development of this inflammatory pathology and its associated
vascular alterations. However, further investigations that deeply
analyze the role of immunity in hypertension and end-organ
damage will help develop therapies for this global disease.
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